Open Orphan (LON: ORPH) has seen its shares surge Wednesday after hVIVO, a subsidiary of Open Orphan, signed a £5.1m contract with a biopharmaceutical company.
The contract will see hVIVO test the biopharma firm’s Investigational Medicinal Product (IMP) using hVIVO’s respiratory syncytial virus (RSV) Human Challenge Study Model.
The study is anticipated to start in H2 2022, with the revenue recognised in 2021 and 2022.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
hVIVO is conducting the study on behalf of the client to demonstrate the efficacy of IMP against RSV infection. The contract win is the second within a few days for Open Orphan after another of its subsidiaries, Venn Life Sciences, signed a contract renewal with a major global pharmaceutical client worth £1.5m.
Cathal Friel, Executive Chairman of Open Orphan, stated: “We are pleased to have signed this contract to test our client’s product using our RSV Human Challenge Study Model.
“It is testament to our position as the world leading provider of Phase IIa human challenge study clinical trials that innovative biopharmaceutical companies, as well as Big Pharma, are actively and regularly engaging us to test their novel vaccine and antiviral candidates.”
Open Orphan shares are up 3.7% at 19.6p following the news. They initially hit a high of 21.22p at the open.
Should you invest in Open Orphan shares?
Open Orphan shares are traded on the London stock exchange’s AIM market (the alternative investment market), which is the submarket specifically for smaller companies. AIM stocks are attractive to investors as they have tax advantages and smaller companies have the potential to benefit from rapid growth. But are ORPH shares the best buy? Our stock market analysts regularly review the market and share their picks for high growth companies
